BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34453533)

  • 21. Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae.
    Martinez-Guerra BA; Xancal-Salvador LF; Esteban-Kenel V; Tello-Mercado AC; Bobadilla-Del-Valle M; Sifuentes-Osornio J; Ponce-de-Leon A; Gonzalez-Lara MF
    J Glob Antimicrob Resist; 2024 Jun; ():. PubMed ID: 38945364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
    Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
    Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
    Stewart AG; Harris PNA; Henderson A; Schembri MA; Paterson DL
    J Antimicrob Chemother; 2020 Sep; 75(9):2384-2393. PubMed ID: 32443141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined relay therapy with oral cefixime and clavulanate for febrile urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Madhi F; Biscardi S; Bingen E; Jaby O; Epaud R; Cohen R
    Pediatr Infect Dis J; 2013 Jan; 32(1):96-7. PubMed ID: 23241996
    [No Abstract]   [Full Text] [Related]  

  • 26. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.
    Doern GV; Brueggemann AB; Pierce G; Holley HP; Rauch A
    Antimicrob Agents Chemother; 1997 Feb; 41(2):292-7. PubMed ID: 9021182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibacterial effect of cefixime in the presence of the type of beta-lactamases produced by Enterobacteriaceae].
    Philippon A; Jarlier V; Legrand P; Fournier G; Nicolas MH; Duval J
    Presse Med; 1989 Oct; 18(32):1560-6. PubMed ID: 2530532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disc diffusion-based screening tests for extended-spectrum beta-lactamases in Haemophilus influenzae.
    Tristram SG; Bozdogan B; Appelbaum PC
    J Antimicrob Chemother; 2005 Apr; 55(4):570-3. PubMed ID: 15728142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
    Zykov IN; Frimodt-Møller N; Småbrekke L; Sundsfjord A; Samuelsen Ø
    Int J Antimicrob Agents; 2020 Feb; 55(2):105851. PubMed ID: 31770624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.
    Madhi F; Jung C; Timsit S; Levy C; Biscardi S; Lorrot M; Grimprel E; Hees L; Craiu I; Galerne A; Dubos F; Cixous E; Hentgen V; Béchet S; ; Bonacorsi S; Cohen R
    PLoS One; 2018; 13(1):e0190910. PubMed ID: 29370234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with cefpodoxime proxetil in acute otitis media.
    Cohen R
    Pediatr Infect Dis J; 1995 Apr; 14(4 Suppl):S12-8. PubMed ID: 7792125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
    Cohen KA; El-Hay T; Wyres KL; Weissbrod O; Munsamy V; Yanover C; Aharonov R; Shaham O; Conway TC; Goldschmidt Y; Bishai WR; Pym AS
    EBioMedicine; 2016 Jul; 9():170-179. PubMed ID: 27333036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS
    Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group.
    Klein M
    Pediatr Infect Dis J; 1995 Apr; 14(4 Suppl):S19-22. PubMed ID: 7792126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing Prevalence of Group III Penicillin-Binding Protein 3 Mutations Conferring High-Level Resistance to Beta-Lactams Among Nontypeable
    Han MS; Jung HJ; Lee HJ; Choi EH
    Microb Drug Resist; 2019 May; 25(4):567-576. PubMed ID: 30484742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
    Syre H; Hetland MAK; Bernhoff E; Bollestad M; Grude N; Simonsen GS; Löhr IH
    APMIS; 2020 Mar; 128(3):232-241. PubMed ID: 31755584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro Efficacy of Six Alternative Antibiotics against Multidrug Resistant Escherichia Coli and Klebsiella Pneumoniae from Urinary Tract Infections.
    Chen YT; Ahmad Murad K; Ng LS; Seah JT; Park JJ; Tan TY
    Ann Acad Med Singap; 2016 Jun; 45(6):245-50. PubMed ID: 27412057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases.
    Marre R; Schulz E
    Arzneimittelforschung; 1988 Jul; 38(7):863-5. PubMed ID: 3061383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Oral Amoxicillin/Clavulanate for Urinary Tract Infections Caused by Ceftriaxone Non-Susceptible Enterobacterales.
    Salam ME; Jeffres M; Molina KC; Miller MA; Huang M; Fish DN
    Pharmacy (Basel); 2024 Apr; 12(2):. PubMed ID: 38668086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.